>latest-news

PolyPid Appoints Experienced MedTech Executive Brooke Story As Chairman Of Its Board Of Directors

PolyPid appoints Brooke Story as Board Chair to guide growth and commercialization of its surgical infection prevention programs.

Breaking News

  • Dec 17, 2025

  • Simantini Singh Deo

PolyPid Appoints Experienced MedTech Executive Brooke Story As Chairman Of Its Board Of Directors

PolyPid Ltd., a late-stage biopharmaceutical company focused on improving outcomes for surgical patients, announced the appointment of Brooke Story as Chairman of its Board of Directors, effective December 11, 2025. The Company stated that Ms. Story’s appointment comes at an important stage in PolyPid’s growth, as it works to advance its clinical programs toward commercialization. According to Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid, Ms. Story brings deep global experience in the surgical and infection prevention markets, along with a strong background in corporate strategy and business development. 


Her leadership is expected to play a key role in helping the Company translate its clinical progress into commercial success. Ms. Story has more than 25 years of leadership experience in the medical technology sector. She has held senior executive positions at BD (Becton, Dickinson and Company) and Medtronic PLC. Most recently, she served as Worldwide President of BD’s Surgery business, where she was responsible for global strategy and profit-and-loss management across product areas such as hernia repair, tissue repair, and infection prevention.


In addition to her operational leadership experience, Ms. Story has significant expertise in mergers and acquisitions and licensing transactions. She currently serves as BD’s Separation and Integration Lead, overseeing the divestiture of the Life Sciences business and managing complex global integration activities. Ms. Story said she is pleased to join PolyPid at a critical point in its development and looks forward to working with the leadership team. 


She noted that the Company’s drug delivery platform has the potential to address important and costly challenges in surgical infection prevention and to support the creation of long-term value while bringing meaningful innovations to patients and healthcare systems. In parallel with her role at PolyPid, Ms. Story serves as a non-executive director on the Board of LivaNova PLC. She has previously served on the Board of Sigilon Therapeutics, Inc. and as a Board observer for Avation Medical, Inc. She holds a Bachelor of Science in Engineering from the University of Tennessee and an MBA from the University of Michigan.

Ad
Advertisement